These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16708855)

  • 61. MS drug back on market under restricted program.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
    [No Abstract]   [Full Text] [Related]  

  • 62. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [New era for MS treatment. Severe setback when it comes to enthusiasm--highly effective agent caused serious adverse effects].
    Olsson T
    Lakartidningen; 2006 Apr 26-May 2; 103(17):1282-3. PubMed ID: 16708855
    [No Abstract]   [Full Text] [Related]  

  • 64. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices.
    Giovannoni G; Kinkel P; Vartanian T
    Rev Neurol Dis; 2007; 4(4):184-93. PubMed ID: 18195670
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R; Wekerle H
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B; Kappos L
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Daclizumab treatment for multiple sclerosis.
    Kim SE
    Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biological agents: new drugs, old problems.
    Muñoz-Cano R; Carnés J; Sanchez-Lopez J; Saiz A; Bartra J; Lopez-Matas MA; Picado C; Valero A
    J Allergy Clin Immunol; 2010 Aug; 126(2):394-5. PubMed ID: 20579714
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.